Drugs / ABBV-461
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06878248 | Apr 2025 → Apr 2026 | HER2 positive breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Calibr, a division of Scripps Research | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-461 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06878248 ↗ |
| Modality | Protein / enzyme biologic | “an Antibody-Based Biologic” NCT06878248 ↗ |